 
 |
|
Celladon Corp. Announces that MYDICAR® Meets Primary Endpoint in Phase 2 Trial for Treatment of Advanced Heart Failure
Date: April 28, 2010
Client: Celladon Corp.
Summary: LA JOLLA, Calif., April 28, 2010 – Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that its first Phase 2 trial with MYDICAR® for the treatment of advanced heart failure has met the prospectively defined safety and efficacy endpoints for the trial as defined in the Phase 2 clinical trial protocol.
|
|
|
|
 |
|
Debiopharm Group™ starts Phase I clinical trial with Debio 0932
Date: April 27, 2010
Client: Debiopharm Group™
Summary: Lausanne, Switzerland – April 27, 2010 - Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and which has embarked in the field of companion diagnostics with a view to progressing in the area of personalised medicine, today announced that it has started patient enrolment in its Phase I clinical trial for the small molecule inhibitor of heat shock protein 90 (Hsp90), Debio 0932. This trial will evaluate the maximum tolerated dose and safety of Debio 0932 in patients suffering from advanced solid tumours or lymphoma.
|
|
|
|
 |
|
Pluristem Therapeutics Announces Interim Top-Line Results from PLX–PAD Clinical Trials Data Demonstrates PLX-PAD is Safe and Effective
Date: April 27, 2010
Client: Pluristem Therapeutics Inc.
Summary: HAIFA, Israel, April 27, 2010 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (DAX:PJT) today announced interim top-line results from its Phase I clinical trials utilizing its placenta-derived cell therapy product, PLX-PAD, for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD). The interim data demonstrated that PLX-PAD is safe, well tolerated and effective.
|
|
|
|
|
|
Pluristem Therapeutics Raises $2.7 Million in Private Placement of Restricted Common Stock
Date: April 27, 2010
Client: Pluristem Therapeutics Inc.
Summary: HAIFA, Israel, April 27, 2010 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (DAX:PJT) today announced that it has entered into definitive agreements with selected investors to sell restricted common stock and warrants for aggregate gross proceeds of approximately $2.7 million. The offering includes 2,420,293 shares of common stock, warrants to purchase 726,088 shares of common stock at an exercise price of $1.25 per share and warrants to purchase 726,088 shares of common stock at an exercise price of $1.40 per share. The warrants will be exercisable for a period of two and a half years and five years respectively commencing six months following the issuance thereof. The closing is scheduled to take place no later than close of business today, April 27, 2010.
|
|
|
|
 |
|
Pluristem stem cell treatment shows early promise
Date: April 27, 2010
Client: Pluristem Therapeutics Inc.
Summary: NEW YORK, April 27 (Reuters) - Pluristem Therapeutics Inc (PSTI.O) said on Tuesday its experimental stem cell treatment appeared to be safe and showed promise in treating a serious arterial blood flow condition called critical limb ischemia, according to interim data from a tiny Phase I study.
|
|
|
|
 |
|
Cellular Dynamics Raises $40.6 MM to Revolutionize Pharma Drug Research with Industrial Manufacture of Human Heart and Other Cells
Date: April 27, 2010
Client: Cellular Dynamics International, Inc.
Summary: MADISON, Wis., April 27, 2010 – Cellular Dynamics International, Inc. (CDI), already the world’s highest volume manufacturer of human heart cells, has closed on a $40.6 million Series B private equity round. This financing enables the company to increase production capacity for its iCellTM Cardiomyocytes, human heart cells derived from induced pluripotent stem cells (iPSCs), and to launch additional human tissue cell products for biomedical and pharmaceutical drug development and safety research. CDI also plans to use the proceeds to rapidly expand its commercial organization to meet the growing demand for these iPSC-based products. CDI has raised a total of $70 million since 2004.
|
|
|
|
 |
|
TR10: Engineered Stem Cells
Date: May/June 2010
Client: Cellular Dynamics International
Summary: The small plastic vial in James Thomson's hand contains more than 1.5 billion carefully coddled heart cells grown at Cellular Dynamics, a startup based in Madison, WI. They are derived from a new type of stem cell that Thomson, a cofounder of the company, hopes will improve our models of human diseases and transform the way drugs are developed and tested.
|
|
|
|
 |
|
Aragon Pharmaceuticals Secures $22 Million in Series B Financing
Date: April 22, 2010
Client: Aragon Pharmaceuticals Inc.
Summary: Aragon Pharmaceuticals Inc. today announced that it has secured $22 million in Series B financing.
|
|
|
|
|
|
Cellular Dynamics International’s iCellTM Cardiomyocytes, Derived From Human iPSCs, Named to MIT Technology Review’s Annual 10 Emerging Technologies List
Date: April 21, 2010
Client: Cellular Dynamics International
Summary: MADISON, Wis., April 21, 2010 – Cellular Dynamics International (CDI) today announced that CDI’s development and commercialization of human cardiomyocytes for drug discovery and toxicity testing, based on the work of CDI co-founder and chief scientific officer, James A. Thomson, Ph.D., on induced pluripotent stem cell (iPSCs) technology, have been named to the MIT Technology Review’s Annual 10 Emerging Technologies List.
|
|
|
|
 |
|
OrbusNeich Announces Full Availability of Genous(TM) Bio-engineered Cobalt Chromium Stent Following CE Mark Approval
Date: April 20, 2010
Client: OrbusNeich
Summary: HONG KONG, April 20 /PRNewswire/ -- OrbusNeich announced that following CE Mark (Conformite Europeenne) approval, its Genous Bio-engineered Cobalt Chromium Stent is now commercially available.
|
|
|
|
 |
|
GlobeImmune’s Hepatitis C Product Candidate Improves End of Treatment Response in All IL-28 B Genotypes, with the Greatest Effect in the Hardest-to-Treat Patients
Date: April 19, 2010
Client: GlobeImmune, Inc.
Summary: LOUISVILLE, Colo., April 19, 2010 – GlobeImmune Inc. announced Phase 2b data for GI-5005, the Company’s investigational Tarmogen® product for hepatitis C virus (HCV) infection, correlating GI-5005 treatment response rate and IL-28 B genotype in patients with chronic HCV infection.
|
|
|
|
|
|
GlobeImmune GI-5005 HCV Product Candidate Improves Sustained Virologic Response by 10 Percent, Demonstrating Potential to be First Therapeutic Vaccine for HCV
Date: April 15, 2010
Client: GlobeImmune, Inc.
Summary: LOUISVILLE, Colo., April 15, 2010 – GlobeImmune, Inc. today announced final Phase 2b data for GI-5005, the Company’s investigational Tarmogen® product candidate, demonstrating its potential to be the first successful therapeutic vaccine for chronic hepatitis C virus (HCV) infection. The data show that GI-5005 increased the sustained virologic response (SVR) in genotype 1 interferon-naïve patients to 58 percent when used in combination with standard of care (SOC), pegylated interferon-a2a plus ribavirin, versus 48 percent for patients receiving SOC alone. The study also demonstrated that adding GI-5005 to SOC results in an improvement in normalization of alanine aminotransferase (ALT) levels and suggests an improvement in liver biopsies, both markers used to assess liver damage.
|
|
|
 |
|
72% of Patients Receiving ANA598 in Phase II Combination Study With Interferon and Ribavirin Achieve Undetectable Levels of Virus at Week Eight
Date: April 15, 2010
Client: Anadys Pharmaceuticals, Inc.
Summary: SAN DIEGO, April 15, 2010 -- Anadys Pharmaceuticals, Inc. announced today that 72% of hepatitis C patients receiving ANA598 400 mg twice daily (bid) plus standard of care (SOC) achieved undetectable levels of virus at week eight in an ongoing Phase II study, compared to 38% of patients receiving placebo plus SOC.
|
|
|
|
 |
|
Regulators to Review New Drugs to Curb Appetite
Date: April 13, 2010
Client: Arena Pharmaceuticals Inc.
Summary: A new generation of anti-obesity drugs could hit the market in coming months, the latest attempt in what has proved a difficult medicine to make safe for patients. Insert Summary here
|
|
|
|
 |
|
Cempra pharmaceuticals presents new data on its multi-drug resistant anti-infective portfolio, cem-101 and takstatm (cem-102), at the 20th european congress of clinical microbiology and infectious disease
Date: April 10, 2010
Client: Cempra pharmaceuticals
Summary: Chapel Hill, N.C., Apr. 10, 2010 - Cempra Pharmaceuticals today announced poster presentations on its novel antibiotic CEM-101, a next-generation macrolide, and CEM-102 (TAKSTA), the company's proprietary front-loading oral dosing regimen of sodium fusidate, at the 20th European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 10 to 13, 2010, in Vienna Austria. All presentations are scheduled for 12:30 to 1:30 p.m. CET on Sunday, April 11.
|
|
|
|
 |
|
Cancer Diagnostics Seek to Fulfill Promise
Date: April 2010
Client: febit
Summary: Personalized medicine, the application of genomic and molecular data to better target disease states, has been defined as a novel therapeutic concept for over a decade. At CHI’s “Molecular Medicine Tri Conference,” held recently in San Francisco, presenters demonstrated how the early promise of personalized medicine in cancer molecular diagnostics is now being realized.
|
|
|
|
 |
|
Otonomy Announces Patent Grant in United Kingdom
Date: April 7, 2010
Client: Otonomy, Inc.
Summary: SAN DIEGO, April 7 /PRNewswire/ -- Otonomy, Inc. today announced that the U.K. Intellectual Property Office has granted patent number GB2459910, titled, "Controlled Release Corticosteroid Compositions and Methods for the Treatment of Otic Disorders."
|
|
|
|
 |
|
Ardea Biosciences, Inc. Announces Pricing of Public Offering of Common Stock
Date: April 6, 2010
Client: Ardea Biosciences, Inc.
Summary: SAN DIEGO, April 6, 2010 /PRNewswire via COMTEX/ --Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced the pricing of a public offering of 3,500,000 shares of its common stock. The offering is expected to close on or about April 9, 2010, subject to customary closing conditions. In addition, Ardea Biosciences has granted the underwriters a 30-day option to purchase up to an additional 525,000 shares to cover overallotments, if any.
|
|
|
|
|
|
Cempra Announces Expansion of Clinical Management Team to Advance Leading Antibacterial Clinical Programs TAKSTA(TM) and CEM-101
Date: April 6, 2010
Client: Cempra Pharmaceuticals
Summary: CHAPEL HILL, N.C., April 6 /PRNewswire/ -- Cempra Pharmaceuticals today announced the expansion of its clinical development team to manage the company's leading clinical programs, CEM-101 and TAKSTA (formerly CEM-102) through advanced clinical development. The four appointments, including Susan R. Moriarty, M.D. and Jennifer Schranz, M.D., have significant antibiotic clinical development experience.
|
|
|
|
 |
|
Helix BioPharma to Present at the BioFinance 2010 Conference on April 7
Date: April 5, 2010
Client: Helix BioPharma
Summary: AURORA, Ontario, April 5 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: "HXBPF") today announced that John Docherty, president and chief operating officer, will present at the BioFinance 2010 Investor Conference at 10:00 a.m. EDT on Wednesday, April 7th, at The Toronto Marriott in Toronto, Canada. Mr. Docherty will provide an overview of the Company's leading product development programs Topical Interferon Alpha-2b and L-DOS47. The slideshow portion of the presentation will be posted on the Company's website, www.helixbiopharma.com, on April 7th, 2010.
|
|
|
|
|
